Entellus Medical Inc. (NASDAQ:ENTL) saw strong trading volume on Wednesday . 58,150 shares were traded during mid-day trading, a decline of 14% from the previous session’s volume of 67,781 shares.The stock last traded at $18.36 and had previously closed at $18.60.

Several research analysts recently weighed in on ENTL shares. BTIG Research started coverage on Entellus Medical in a research report on Tuesday, June 14th. They issued a “buy” rating and a $22.00 price objective for the company. Zacks Investment Research lowered Entellus Medical from a “hold” rating to a “sell” rating in a research report on Thursday, April 14th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $23.00 price objective on shares of Entellus Medical in a research report on Wednesday, June 29th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Entellus Medical currently has a consensus rating of “Buy” and an average target price of $23.80.

The stock has a 50-day moving average of $17.98 and a 200 day moving average of $16.76. The company’s market capitalization is $343.99 million.

Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Wednesday, May 4th. The medical technology company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.10. During the same quarter last year, the company earned ($0.35) EPS. The business had revenue of $16.90 million for the quarter, compared to analyst estimates of $16.34 million. Entellus Medical’s revenue was up 25.2% compared to the same quarter last year. Analysts predict that Entellus Medical Inc. will post ($1.32) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Entellus Medical stock. Wells Fargo & Company MN raised its stake in Entellus Medical Inc. (NASDAQ:ENTL) by 7.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 464,550 shares of the medical technology company’s stock after buying an additional 31,082 shares during the period. Wells Fargo & Company MN owned approximately 2.47% of Entellus Medical worth $7,832,000 as of its most recent SEC filing.

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses.